相关实验视频

Updated: May 7, 2025

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

CD73:病原体开发潜力及其在糖尿病和动脉样硬化中的应用

Dan Liu¹, Jingjing Zhao², Ling Li³

¹Guangdong Provincial People's Hospital, Zhuhai Hospital (Jinwan Central Hospital of Zhuhai), Zhuhai, Guangdong, China.

Frontiers in immunology

|December 30, 2024

概括

CD73是一种影响新陈代谢和免疫力的基因,在糖尿病和动脉样硬化中具有双重作用. 通过各种药物的调制显示出治疗这些疾病的潜力,circNT5E成为新的标.

科学领域:

生物化学生物化学
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

CD73将腺单酸盐 (AMP) 催化为腺 (ADO),影响炎症和免疫反应.
CD73表现出上下文依赖的作用,在糖尿病中起保护作用,但随着年龄的增长而起动脉样硬化作用.
CD73的双重性质需要对治疗开发有细微的理解.

研究的目的:

审查目前关于CD73在糖尿病和动脉样硬化中的作用的知识.
探索针对CD73的药物的治疗开发潜力.
为了突出新兴的目标,如circNT5E调节CD73表达.

主要方法:

在代谢和血管疾病中对CD73功能研究的文献综述.
对调高或调低CD73活性的药物的分析.
对CD73调节疗法的临床试验数据的检查.
研究与CD73.3相关的非编码RNA,如circNT5E.

主要成果:

通过各种药物对CD73的升级显示出降低糖尿病和动脉样硬化的前景.
降低CD73的调节也在减少动脉样硬化方面表现出有效性.
虽然许多CD73药物正在试验中,但没有一种药物被批准用于糖尿病或动脉样硬化;大多数是抑制剂.
鉴定出circNT5E是CD73表达的促进剂,这表明它是潜在的治疗标.

结论:

CD73是一个复杂但有前途的目标,用于治疗糖尿病和动脉样硬化.
进一步研究CD73调制和新目标,如circNT5E是有效的药物开发的必要条件.
开发CD73特异性疗法需要仔细考虑其双重作用和潜在的副作用.

关键词:

CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73 开发代理商发展代理商动脉样硬化动脉样硬化圆圈NT5E 在线观看糖尿病糖尿病患者糖尿病患者

更多相关视频

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer

Published on: October 10, 2012

相关概念视频

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...